Drug intelligence / Profile preview

SP-015

Development stage: Preclinical
Lead developer: Sunny Pharmtech
Modality: Small Molecules
Administration: Oral

Overview

SP-015 is a small molecule therapeutic candidate developed by Sunny Pharmtech for the treatment of eosinophilic esophagitis (EoE). It is formulated as an oral suspension and is categorized as a high-potency (OEB4) product within the company's pipeline. Currently in the research and development (R&D) stage, SP-015 represents Sunny Pharmtech's expansion into specialized gastrointestinal treatments using their expertise in complex formulations and high-potency active pharmaceutical ingredients.

Beyond the preview

Go deeper on SP-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-015.

Explore the full profile